Drug intelligence / Profile preview

goserelin + aromatase inhibitor

Development stage: Unknown
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

Combination therapy of goserelin with an aromatase inhibitor (anastrozole, letrozole, or exemestane) used primarily for hormone receptor-positive breast cancer in premenopausal women. Goserelin suppresses ovarian function by downregulating LHRH receptors, creating a postmenopausal-like hormonal environment, while the aromatase inhibitor blocks the conversion of androgens to estrogens in peripheral tissues, further reducing estrogen levels.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on goserelin + aromatase inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on goserelin + aromatase inhibitor.

Explore the full profile